BiomX (NYSEMKT:PHGE) Shares Down 14.9% – Should You Sell?

BiomX Inc. (NYSEMKT:PHGE)’s share price dropped 14.9% on Thursday . The stock traded as low as $0.72 and last traded at $0.63. Approximately 53,300 shares changed hands during trading, a decline of 14% from the average daily volume of 61,836 shares. The stock had previously closed at $0.74.

BiomX Stock Down 14.9 %

The company has a market cap of $11.43 million, a price-to-earnings ratio of -0.84 and a beta of 1.38. The stock has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.79. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On BiomX

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of BiomX during the fourth quarter worth $314,000. Allostery Investments LP purchased a new position in BiomX in the 4th quarter worth about $470,000. Alyeska Investment Group L.P. acquired a new stake in BiomX during the 4th quarter worth about $632,000. Finally, Ikarian Capital LLC purchased a new stake in BiomX during the third quarter valued at about $911,000. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.